Steven A. Middleton

La Roche College — United States

Medicine · Health Sciences

32h-index4.6kcitations81works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(22), Receptor Mechanisms and Signaling(9), Chronic Lymphocytic Leukemia Research(8), Advanced Breast Cancer Therapies(8), Urinary Bladder and Prostate Research(7)

Publications81 total

Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma
Leukemia & lymphoma/Leukemia and lymphoma·2017· 11 cited
Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist
Blood·2016· 7 cited
The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models
Blood·2016· 2 cited
Interview with Morris L. Norfleet
ScholarWorks - MoreheadState (Morehead State University)·2016
Interview with Jim Wells
ScholarWorks - MoreheadState (Morehead State University)·2016
Interview with J. D. Reeder.
ScholarWorks - MoreheadState (Morehead State University)·2016
Interview with Wayne Martin
ScholarWorks - MoreheadState (Morehead State University)·2016
Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells
Blood·2015
Abstract A156: Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration
Molecular Cancer Therapeutics·2015· 4 cited
Abstract 2835: MDM2 antagonist-based therapeutic response is discriminated by a 4-gene signature in acute myeloid leukemia patients
Cancer Research·2015
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology·2015· 65 cited
<scp>MDM</scp>2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia
British Journal of Haematology·2015· 20 citedOpen Access
Inhibition of MDM2 by RG7388 confers hypersensitivity to X‐radiation in xenograft models of childhood sarcoma
Pediatric Blood & Cancer·2015· 26 citedOpen Access
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
Oncotarget·2015· 89 citedOpen Access
A selective small molecule NOP (ORL-1 receptor) partial agonist for the treatment of anxiety
Bioorganic & Medicinal Chemistry Letters·2014· 17 citedOpen Access
Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)
Blood·2014· 82 cited
Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.
Journal of Clinical Oncology·2014· 66 cited
Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine
Blood·2013· 22 cited
Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS).
Journal of Clinical Oncology·2013· 23 cited
Abstract LB-201: Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.
Cancer Research·2013· 2 cited
page 1 of 5Next →

Frequent Co-authors

Peter J. Connolly(24), Stuart L. Emanuel(19), Linda K. Jolliffe(14), Angel R. Fuentes‐Pesquera(14), Robert H. Gruninger(14), Gwen Nichols(10), Dana L. Johnson(9), Jianguo Zhi(8), Ronghui Lin(7), William V. Murray(7), Mary Adams(7), Steven K. Wetter(6), Terry V. Hughes(6), Sandra Moreno-Mazza(6), Catherine A. Rugg(6), Evan R. Kantrowitz(6), David Geho(5), Steven Blotner(5), Lee M. Greenberger(5), Oded Livnah(4)